medac and Clinigen expand strategic partnership to improve patient care in the Asia-Pacific region

medac and Clinigen are deepening their existing cooperation to significantly improve healthcare access across the high-growth Asia-Pacific (APAC) region. Six key pharmaceuticals developed by medac in the areas of oncology, haematology, and immune-mediated diseases will now be exclusively marketed and distributed by Clinigen in Australia, parts of Southeast Asia, and China.

The agreement was signed last week at Clinigen’s London offices by Frank Lucaßen, Managing Director of medac, and Jerome Charton, CEO of Clinigen, formalizing the expanded partnership.

This new agreement marks a strategic milestone, further strengthening Clinigen’s position in the APAC pharmaceutical market, which offers substantial growth potential – particularly in oncology, immunology, and rare diseases.

With its established global distribution network, local regulatory expertise, and proven market access strategies, Clinigen is well-positioned to swiftly integrate medac’s innovative treatment portfolio.

Prior to this, medac had already entered into a distribution partnership with Hyphens for one of its key autoimmune products in Southeast Asia. The exclusive Marketing and Distribution Agreement (MDA) with Clinigen is now another crucial step toward internationalizing medac’s therapies.

Jerome Charton, CEO of Clinigen, stated: “Building on our successful relationship with medac is a key moment for Clinigen. We are honored by the continued trust and are committed to expanding access to these six treatments across the APAC region.”

Frank Lucaßen, Managing Director of medac, added: “We see significant potential for our products in the Asia-Pacific region. With Clinigen, we’ve found the ideal partner to improve patient access and substantially grow our business in these dynamic markets.”